BIO-Europe Spring® program in Turin will engage executives in provocative topics facing drug development industry

Life science executives are quickly filling up the program at the eighth annual BIO-Europe Spring®conference to be held March 10–12, 2014 in Turin, Italy. The international bio-pharma partnering event annually attracts top international executives from established and emerging biotech companies; pharmaceutical companies; private investors including venture capital and private equity; companies developing companion diagnostics; and other industry related service companies.

Leading pharmaceutical companies and investors are lead participants in the conference program, and are a major attraction for biotech and service providers hoping to partner with them. These companies include Almirall; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; GE Healthcare; Genentech; GlaxoSmithKline; Johnson &Johnson Development Corporation; Novartis; Novo Nordisk; Roche; Sofinnova Partners and more.

Participants will have the chance to discover the unique biotech enterprises featured in Piemonte. This second largest biotech center in Italy is a perfect venue for this event, hosted by a regional team coordinated by the Torino Chamber of commerce and including theBioindustry ParkPiemonte Agency and Turismo Torino.

Piemonte is home to more than 350 companies employing over 7,000 people: renown multinationals (such as Merck-Serono, Bracco, Sorin, Takeda, Sanofi-Aventis), innovative SMEs (such as AAA, Creabilis, Nobilbio, Nurex, Procelltech, IM3d, Ephoran), a science and technology park focused on biotech (Bioindustry Park), a healthcare innovation cluster (bioPmed), 3 universities, 3 incubators (2i3t, i3p, Ennetre) and several research centers with 3,500+ researchers.

The first day of the program, Monday, March 10, is divided into three parallel tracks, Business Development, In The Spotlight, and Therapeutic Insight by Defined Health. Philippe Lopes-Fernandes, Senior VP and Head of Global Licensing and Business Development at EMD Serono, is participating on the BD panel “Go big or go home: When to go against the trends in R&D and dealmaking.”

“Why does every company boast about being innovation-driven, yet most R&D targets and approaches are the same?” said Lopes-Fernandes. “Is there an R&D ‘fashion victim syndrome’ that makes everyone invest in the same spaces? What is preventing true innovation? Our boards? The regulators? Ourselves? I look forward to discussion on this topic at BIO-Europe Spring.”

Another panel in the BD track called “Asset-centric companies: Still lean and mean or ‘so 2012′?” will discuss whether asset-centric financing will dwindle in light of the recent IPO boon.Francesco De Rubertis, Partner and Co-Founder of Index Ventures, is a speaker on the panel.

“A few years ago there was a paradigm shift toward asset-centric business models, primarily to ensure financial returns even during a high-risk environment,” said De Rubertis. “And now that market confidence has returned, albeit cautiously, the question of revamping toward an adaptive model to fit the public markets is relevant and should make for an interesting panel at BIO-Europe Spring.”

The Defined Health by Therapeutic Insight track features several timely panels, among them the topic “Addressing cognitive deficits across CNS disorders: Potential to improve overall functional outcomes and QoL,” with Dana C. Hilt, MD, Senior VP, Clinical Development and Chief Medical Officer of EnVivo Pharmaceuticals as one of the panelists.

“This will be a compelling discussion on the approach to treatments that can improve cognitive function across various CNS disorders. In many if not most of these conditions, this area represents a significant unmet medical need,” said Hilt. “In addition to improvement in cognition, patient-centered approaches that assess function and overall health outcomes will be key to future success.”

More information on the BIO-Europe Spring 2014 program, including a list of presenting companies, can be found online.

BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship life science partnering conference, BIO-Europe®. Companies participate in one-to-one partnering meeting facilitated by EBD Group’s highly reputable partneringONE® platform.

Register now for BIO-Europe Spring 2014, and read the Spotlight on Turin page to plan your trip.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
  • EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
  • The Global Impact Forum™, a unique and innovative partnering conference in impact investing and venture philanthropy.

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit

About BIO-Europe Spring® 2014

As the springtime counterpart to BIO-Europe®, BIO-Europe Spring® continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s acclaimed partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the biotech value chain.

In addition to productive partnering, BIO-Europe Spring offers high level workshops, panels, company presentations, and a lively exhibition. The program features executive level panelists who openly share their insight and opinion on many important industry issues. The company presentation tracks provide a forum for innovative start-ups, established biotech companies, and large and midsize pharma to present information on products, partnering opportunities and corporate strategy.

Combined, these elements create an insightful and productive event that will have you coming back year after year.

BIO-Europe Spring is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Industry Organization (BIO).

Follow BIO-Europe Spring 2014 on Twitter: (hashtag: #BES14). Or log on to the BIO-Europe Spring 2014 Discussion Forum on partnering360. The Group is your go-to discussion forum for news and topics related to BIO-Europe Spring.